VRT-325
VRT-325 is a novel small molecule discovered by screening a compound library designed to address the genetic defect in cystic fibrosis (CF) caused by the ΔF508 mutation in CFTR. VRT-325 belongs to a class of compounds that promote ΔF508-CFTR efflux from the endoplasmic reticulum and restores chloride transport levels in epithelial cells of CF-derived bronchi[1].
Product Specifications
CAS Number
[815592-21-3]
Product Name Alternative
4-Hydroxy-TEMPO-d17,15N
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CFTR
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/vrt-325.html
Purity
99.15
Smiles
CC(N1CCN(CC1)S(=O)(C2=CC=C(C=C2)OC)=O)C3=NC(OC4CCCCC4)=C5C=CC=CC5=N3
Molecular Formula
C27H34N4O4S
Molecular Weight
510.65
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-119229/VRT-325-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-119229/VRT-325-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
HCFC1R1, NT (HCFC1R1, HPIP, Host cell factor C1 regulator 1, HCF-1 beta-propeller-interacting protein) (MaxLight 750)
